&w=3840&q=100)
Growing pains: NTPC expansion spawns companies and CEOs in equal measure
The diversification into RE also means that NTPC will no longer be bound by a single ministry, a position no other major state-owned company in India has straddled, be it LIC, ONGC, SBI, or Coal India. This effectively makes NTPC, the country's largest energy producer, stand for NTPC Group of companies.
In fact, the NTPC name now pops up in nuclear enterprises, green companies of all shades including solar, wind and even tidal, coal mining, critical mineral mining, and green hydrogen, among others. The latest to join the list could be green chemicals. If one were to look at the numbers NTPC has birthed a new company every single year for the past 10 years. To take on these burgeoning business possibilities, the energy behemoth has also begun to form joint ventures (JV) with state governments (see chart), and is in talks with others.
With consolidated gross fixed assets of Rs 4.04 trillion, NTPC is almost co-terminus with India's energy supply footprint.
Unlike private sector players, such as L&T, India's state-owned companies typically do not have such a range of subsidiaries or JVs. One of the reasons for their reticence has been the delays involved in the process for most projects. For PSUs, approvals must be obtained from the finance ministry's department of investment and public asset management (Dipam), which often means getting the Union Cabinet's nod as well. The other is fiscal comfort, since investors get access to the balance sheet of the parent company.
Bucking the trend, NTPC created Green Energy Ltd with a simple Board approval as a way to occupy the space between the mother company and the older NTPC Renewables. What's more, NTPC Green Energy's chief executive officer, Sarit Maheshwari, does not sit on the company's Board, an unusual management structure for a state-owned company.
The innovation has helped. NTPC Green is now itself a parent with six companies in its fold. The company is on course to raise finance, possibly at even better terms than NTPC, to steer the plans of the Group to develop 60 GW of RE by early next decade. A Reuters report earlier this month noted that NTPC Green Energy will make its debut in the bond market, raising upwards of Rs 20 billion through five-year bonds. While the rates are not yet public, they are likely to be better than NTPC would get as a coal-based power producer. Once the decision is made to foray into green chemicals (atoms that do not create pollution), the name of the company could be broadened accordingly, a company source said.
Do these surfeit of companies make the span of control within the group difficult? It is a question that Gurdeep Singh, chairman of NTPC for almost a decade now, considers often.
Financing made easy
Singh acknowledges that one of the reasons for setting up separate companies instead of incorporating them as divisions within the mothership was finance. There was the need to create space to invest within the relative financial rigidity under which state owned companies operate in India. The step-down process or JVs allows these companies to raise money on their balance sheet, without necessarily using the NTPC signage.
Another reason is that the chase for new opportunities in India's difficult energy market has its own costs. For instance, owning NTPC Mining to mine coal is a peculiar venture for a power company to be involved in, since it then needs to straddle both ends of the supply chain. At 46 million metric tonnes (MMT) of extraction in FY25, it is on track to become the second largest government miner after Coal India and possibly more efficient. But the mines supplied only about 15 per cent of NTPC's total coal needs for its 53 GW of thermal plant capacity. To wit, NTPC would have been better off hiving off the business to a specialist mine development/operator company. But the mining unit is unlisted, and unlike Green Energy Ltd, would likely see muted investor interest.
Not surprisingly, the NTPC stock has consequently underperformed the market for a long time, despite having a rating equivalent to India's sovereign grade. Bank of America Securities has only recently upgraded the company from 'underperform' to 'neutral', citing valuation correction. The securities firm noted NTPC has trailed the Nifty index by 21 per cent and other defensive sectors, including IT, pharmaceuticals, and consumer staples, by 10-20 per cent since August 2024.
Adopting a culture of risk
'Creating the human resources hunger for performance has been one of my biggest challenges for these ventures,' says Singh. Becoming CEOs of these downstream companies meant prodding the officers to take risks, something that a public-sector culture doesn't exactly promote. 'The company now regularly sends officials to be picked up by the Public Sector Enterprises Board as chief executives of other companies," he says, noting that this was most unusual a few years ago.
The creation of subsidiaries has helped, given the circumstances, and is most evident in the latest: NTPC Parmanu Urja Nigam Limited, established January 2025 as a wholly-owned subsidiary to explore advanced nuclear technologies, including pressurised water reactors, small modular reactors and fast breeder reactors. The company already operates under a company in this space, Ashvini, a JV with NPCIL established in FY25, and which is building the Mahi Banswara Rajasthan Atomic Power Project, comprising four 700 MW reactors.
Singh is unwilling to commit if the two companies will be merged in the future. But he is clear that he will not get into the business of manufacturing nuclear products, even though the best margin lies in manufacturing them in what is an intensely capital-intensive business. After all, there remain some constraints in being the chief of a state-run company, even one as large as NTPC: some decisions are still made outside of New Delhi's NTPC Bhawan.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Mint
11 minutes ago
- Mint
Nifty Pharma index rises 1.9%: Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?
Stock Market Today: The Nifty Pharma index gained 1.9% during the intraday trades on Wednesday. Alkem and Zydus stood among key gainers that led the rally The Nifty Pharma Index gained almost 2% during the intraday trade on Wednesday amid a relief rally in the Indian stock market. The Nifty Pharma Index opened at 21,803.45 levels, higher than the previous day's closing price of 21,753.50. It continued to gain further to an intraday high of 22,171.05, which meant gains of almost 2% over the previous day's close. Alkem Laboratories, Zydus Lifesciences, Laurus Labs, and Abbott India were among the key gainers that led to the rise in the Nifty Pharma pack. The US market remains critical for many Indian pharma companies. Sun Pharmaceuticals, Lupin , Dr. Reddy's, Aurobindo, Cipla, and many more derive a significant part of revenues from the US markets. Thus the danger of a 50% tax on pharmaceuticals looms, and this clearly poses a risk to the profitability of Indian pharmaceutical businesses, which rely on the US market for 30-50% of their sales. Most of these US revenues, however, come from the generic drug segment. Silver lining The silver lining remains as India remains cost-competitive compared to both the US and global peers, which should help mitigate some risks, said Ajit Banerjee, president and chief investment officer at Shriram Life Insurance. The domestic Indian pharma market (50% of the Indian pharmaceutical market) will remain unaffected by tariffs. Within the US, the impact on the generic formulations market is still uncertain, though Indian players already operate on thin margins. Tariffs could increase the drug shortages by eliminating competition in a market where pricing pressures are already intense, which could be a positive for Indian companies over the mid- to long-term, highlighted Banerjee While the recent executive order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. Any tariff action will depend on the outcome of the ongoing investigation under Section 232 of the Trade Expansion Act of 1962. Even if the India pharma tariff question is answered, Kotak Institutional expect the uncertainty to persist around whether the anticipated pharma tariffs (post the Section 232 investigation) would add to the country-specific one, definition of pharma/pharma products and then eventually how much of the tariffs are passed on and rolled back Bannerjee believes the US can either bring manufacturing back home or reduce drug prices, but not both simultaneously. Even before tariffs are finalized, the uncertainty can lead to delays in order commitments and impact sector sentiment and stock price thereby. The sector currently trades at a 1Y forward P/E of 29.7 times, above its 10-year average of 26.7x. We see tariff-induced volatility as a chance for investors to accumulate quality pharma stocks on dips, said Banerjee. Nifty Pharma has witnessed two weeks of selling pressure, especially after the recent U.S. tariff developments, as per analysts. The Pharma Index was trading near a support level on the daily time frame, where a pause in the decline was expected in the coming days, potentially leading the index towards 21,998. The outlook remains negative as long as the index fails to sustain above 22,380. On the downside, a break below 21,240 could push the index further towards the 20,380–20,140 zone, as per Kunal Kamble, Sr. Technical Research Analyst at Bonanza * Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.


Mint
11 minutes ago
- Mint
Bulls ride high on India stocks, expecting success of US-Russia talks on Ukraine
Bulls appeared to be taking charge of the stock markets on Wednesday, ahead of the Trump-Putin talks, where a breakthrough or an impasse could significantly impact Indian equities. The two leaders are slated to meet in Alaska on Friday in a bid to end the over-three year Ukraine war. A day after foreign portfolio investors trimmed their index future longs to 7.95%, only 20 basis points shy of the record low of 7.75% on 22 March 2023, in light of the US Fed rate tightening cycle, bulls sold huge quantities of put options between the 24,500 and 24,600 levels, expecting a rally in the markets ahead of the talks. The contracts expire tomorrow. The Nifty 50 traded 0.6% higher at 24,634 at 1 pm. Amid likely domestic institutional investor buying in the cash market, bulls sold a massive number of puts at 24,600 – the open position at this strike rose by a whopping 227,758 contracts to a total 284,785 contracts. At 24,550, the open or outstanding positions jumped 148,077 contracts to 193,635 contracts and at 24,500 by 152,528 contracts to 260,034 contracts. The jump in open positions at these levels indicates that bulls expect the markets to close at or above 24,600, which will enable them to pocket the premium paid by the put buyers, who expect the markets to correct. "The correction premise (of put buyers) is based on the talks stalling and a continuation of the war, which could impact countries like India that buy Russian oil and have been slapped with a proposed punitive tariff of 25% from 27 August," explained SK Joshi, a consultant with Khambatta Securities. Other analysts cautioned that it was too early to take such calls because the Indian markets would react to the outcome of the talks only on Monday, with Friday a holiday for Independence Day. "The market is likely to consolidate in a 24,400-24,700 range ahead of the Russia-US talks in Alaska," said Sahaj Agrawal, head of derivatives research at Kotak Securities. "The reaction to the outcome will be on Monday." Options data and sentiment for now also suggest a sideways movement, with no major horizon shift on the cards, he added. The put-call ratio of the weekly options expiring on Thursday stood at 0.99 intraday, which means that for every 100 calls sold, traders had sold 99 puts. On Tuesday, the ratio stood at 0.65, or only 65 puts sold for 100 calls sold. Time correction The benchmark Nifty 50 has been in a time correction for 11 months now, which is longer than the nine-month time correction that followed the outbreak of the covid pandemic in 2020. Time correction implies an extended period of stagnant to marginally lower price movement. The Nifty has fallen 6.25% from a record high of 26,277.35 on 27 September last year to Wednesday's intraday level of 24,634. While the Nasdaq, the UK's FTSE and Japan's Nikkei trade at record highs, Indian stock indices haven't been able to reclaim their previous high even 11 months later. In the last major down-cycle, the Nifty fell 40% from a high of 12,430 on 20 January 2020 to 7,511.10 on 24 March that year when the pandemic surfaced. However, it reclaimed the high in nine months, closing at 12,632 by 9 November. The current time correction is due to tepid earnings growth and more lately because of Trump's crushing tariffs on India, which Moody's expects could trim its current fiscal growth estimate by 30 bps to 6%. "We have been in a time correction for nearly 11 months now and will have to see how the geopolitical events play out to reckon whether we will break through the 26,277.35 record high of last September or test the multi-month low of 21,743.65 of this April," Kotak Securities' Agrawal added.

Mint
11 minutes ago
- Mint
Should Indian stock market investors be worried about the IPO boom? Explained
The Indian primary market is on fire. 2025 has already seen a record number of filings, blockbuster listings, and frenzied investor interest across both mainboard and SME initial public offerings (IPOs). Not only have they caught retail investor interest, but the IPO euphoria is also visible in the investment trends of the institutional investors. Till July 2025, 163 public offerings have hit the market, looking to raise ₹ 67,000 crore, according to Prime Database. In August, too, there is no slowdown in the number of offerings, with many big names like JSW Cement, having accessed the IPO market and a few more lined up. G Chokkalingam, Founder, Equinomics Research, explained that the lure of strong listing gains, higher allocation by institutions and retail investors, along with a greater share of offerings from sectors not impacted by the US tariffs, is powering the IPO boom. However, as IPO-bound companies soak up massive capital inflows, especially from FPIs and mutual funds, questions are emerging: Is this IPO boom weighing down the broader market? Are the bulls in the secondary market being kept in check? And what are its implications for the Indian stock market? According to analysts, while IPOs are siphoning liquidity away from the secondary market, the primary market boom is an important feature and a necessary development. Chokkalingam said that a robust IPO market is certainly contributing to the weakness we are seeing in the secondary market. Liquidity at any point in time is limited, he explained, adding that the IPO market competes with the liquidity that would otherwise chase the secondary market and is one of the reasons pressuring the stock market bulls. There has been a record IPO filing in both the mainboard and SME segments, along with bearish flows by FPIs in the secondary markets. FPIs have preferred the IPO market over the secondary market in 2025 as they have pulled out around $17.4 billion from listed equities and invested $4.37 billion in the primary market. The mutual fund industry also demonstrated strong participation in newly-listed companies during the quarter ended June 2025, with total investments exceeding ₹ 5,294 crore across recent IPOs. Vaqarjaved Khan, CFA, Sr. Fundamental Analyst, Angel One, said a strong IPO pipeline can pressurise secondary markets as liquidity diversion for marquee investors tends to happen as they often sell existing holdings to raise cash for attractively priced IPOs. This is more pronounced when IPOs are bunched together and large in size, and the investment window is small, Khan said. There tends to be a valuation reset as well if companies in the primary market are better priced than their listed counterparts, said Khan. This, he believes, results in de-rating in the secondary markets. Sharing a contrasting view, Harshal Dasani, Business Head at INVasset, said that while short-term market momentum may face occasional pressure, in the long run, a steady flow of quality listings strengthens market breadth, price discovery, and overall stability. "With SIP inflows exceeding ₹ 28,000 crore a month and mutual fund AUM at record highs, India is awash with investable capital. If fresh supply through listings dries up, this relentless flow would be forced into a limited set of existing stocks, inflating valuations and creating bubble-like conditions," he added. This isn't the first time India's markets have danced to this tune. 'Over the last 30 years, we've repeatedly seen a pattern: first a secondary market boom, followed by an IPO boom, and then a correction,' said Chokkalingam. According to Chokkalingam, the eventual correction — often prolonged — begins once liquidity tightens and valuations lose support. 'Corrections usually last six months to three years. What brings the market back is time, bottom-fishing, improving valuations, and fresh inflows.' However, what can eventually pull the Indian stock market bulls out of slumber is the resolution of the US-India trade deal and any rate cuts by the US Federal Reserve. "On the domestic front, SIP and domestic flows continue to remain strong. Strong quarterly results from heavyweight sectors, coupled with higher liquidity, will then boost Indian equities and take it out of consolidation," Khan said. Disclaimer: This story is for educational purposes only. The views and recommendations expressed are those of individual analysts or broking firms, not Mint. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.